Dilacor XR

Dilacor XR is a brand name of diltiazem, approved by the FDA in the following formulation(s):

DILACOR XR (diltiazem hydrochloride - capsule, extended release; oral)

• 
  Manufacturer: WATSON LABS
  
  Approval date: May 29, 1992
  
  Strength(s): 120MG ^[AB2], 180MG ^[AB2], 240MG ^[RLD][AB2]

Has a generic version of Dilacor XR been approved?

A generic version of Dilacor XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Dilacor XR and have been approved by the FDA:

diltiazem hydrochloride capsule, extended release; oral

• 
  Manufacturer: APOTEX
  
  Approval date: August 6, 1998
  
  Strength(s): 240MG ^[AB2]


• 
  Manufacturer: APOTEX
  
  Approval date: December 19, 2000
  
  Strength(s): 120MG ^[AB2], 180MG ^[AB2]


• 
  Manufacturer: MYLAN
  
  Approval date: March 18, 1998
  
  Strength(s): 120MG ^[AB2], 180MG ^[AB2], 240MG ^[AB2]


• 
  Manufacturer: WATSON LABS FLORIDA
  
  Approval date: October 10, 1997
  
  Strength(s): 120MG ^[AB2], 180MG ^[AB2], 240MG ^[AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dilacor XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tablets with controlled-rate release of active substances
  Patent 5,422,123
  Issued: June 6, 1995
  Inventor(s): Conte; Ubaldo & La Manna; Aldo & Colombo; Paolo
  Assignee(s): Jagotec AG
  Tablets with zero order controlled-rate of release of the active substances, consisting of a core of defined geometrical form containing the active substance, polymer substances which swell on contact with aqueous liquids and polymer substances with gelling properties, and a support applied to said core to partly cover its surface, the support consisting of polymer substances which are slowly soluble and/or slowly gellable in aqueous liquids, plasticizing substances, and possibly substances with an adjuvant function.
  
  Patent expiration dates:
  
  
  • June 6, 2012
    
  
  

See also...

• Dilacor XR 24-Hour Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Dilacor XR Consumer Information (Cerner Multum)
• Dilacor XR Advanced Consumer Information (Micromedex)
• Diltiazem Consumer Information (Drugs.com)
• Diltiazem Consumer Information (Wolters Kluwer)
• Diltiazem 12-Hour Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Diltiazem 24-Hour Extended-Release Beads Capsules Consumer Information (Wolters Kluwer)
• Diltiazem 24-Hour Extended-Release Beads Tablets Consumer Information (Wolters Kluwer)
• Diltiazem 24-Hour Sustained-Release Beads Capsules Consumer Information (Wolters Kluwer)
• Diltiazem 24-Hour Sustained-Release Capsules Consumer Information (Wolters Kluwer)
• Diltiazem Immediate-Release Tablets Consumer Information (Wolters Kluwer)
• Dilt-CD Consumer Information (Cerner Multum)
• Diltiazem Consumer Information (Cerner Multum)
• Dilt-CD Advanced Consumer Information (Micromedex)
• Diltiazem Advanced Consumer Information (Micromedex)
• Diltiazem Intravenous Advanced Consumer Information (Micromedex)
• Diltiazem Hydrochloride AHFS DI Monographs (ASHP)